US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Q32 Bio Inc.

3.41

-0.4100-10.73%

Post-market: 3.34-0.0700-2.05%17:42 EST

Volume:6.42M

Turnover:24.44M

Market Cap:41.59M

PE:-0.52

High:3.93

Open:3.80

Low:3.23

Close:3.82

52wk High:28.06

52wk Low:1.35

Shares:12.20M

Float Shares:4.73M

Volume Ratio:0.19

T/O Rate:135.77%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-6.5785

EPS(LYR):-5.1211

ROE:-491.67%

ROA:-33.50%

PB:-2.25

PE(LYR):-0.67

Loading ...

Overview Company News Filings

Top Midday Gainers

MT Newswires Live

BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Benzinga_recent_news

Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal

MT Newswires Live

BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline

BRIEF-Q32 Bio Sells Complement Inhibitor Adx-097

Q32 Bio Sells Lead Product Candidate to Akebia Therapeutics

Top Premarket Gainers

MT Newswires Live

Akebia Therapeutics Acquires Global Rights to AKB-097 from Q32 Bio

Akebia Announces Establishment of Rare Kidney Disease Pipeline

THOMSON REUTERS

Akebia Therapeutics: Phase 2 Basket Trial Planned to Evaluate Complement Inhibitor in Multiple Rare Kidney Disease Indications

THOMSON REUTERS

Akebia Therapeutics Inc: Both Trials Planned to Start Treating Subjects in 2026

THOMSON REUTERS

Akebia Therapeutics: Acquires Next Generation Tissue-Targeted C3d-Factor H Fusion Protein Complement Inhibitor From Q32 Bio

THOMSON REUTERS

Akebia Therapeutics Inc: Phase 2 Trial of Praliciguat Initiated in Focal Segmental Glomerulosclerosis (Fsgs)

THOMSON REUTERS

Q32 Bio Inc - Eligible for up to $592 Mln Including Royalties

THOMSON REUTERS

Q32 Bio Inc - $12 Mln Payments Expected to Extend Cash Runway Into Second Half of 2027

THOMSON REUTERS

Press Release: Q32 Bio Sells Complement Inhibitor ADX-097

Q32 Bio (QTTB) Receives a Buy from Oppenheimer

Wells Fargo Remains a Hold on Q32 Bio (QTTB)

Q32 Bio Inc. reports Q3 net loss of $7.4 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/QTTB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"QTTB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QTTB\",,,,,undefined,":{"symbol":"QTTB","market":"US","secType":"STK","nameCN":"Q32 Bio Inc.","latestPrice":3.41,"timestamp":1764709200000,"preClose":3.82,"halted":0,"volume":6420280,"hourTrading":{"tag":"盘后","latestPrice":3.34,"preClose":3.41,"latestTime":"17:42 EST","volume":37634,"amount":125988.056846,"timestamp":1764715346572},"delay":0,"floatShares":4728923,"shares":12197615,"eps":-6.578484,"marketStatus":"Post-Mkt","change":-0.41,"latestTime":"12-02 17:42:39 EST","open":3.8,"high":3.93,"low":3.23,"amount":24435850.195536003,"amplitude":0.183246,"askPrice":3.41,"askSize":212,"bidPrice":3.32,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-6.578484,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"listingDate":1522209600000,"exchange":"NASDAQ","adjPreClose":3.82,"preHourTrading":{"tag":"盘前","latestPrice":3.8,"preClose":3.82,"latestTime":"09:29 EST","volume":1034927,"amount":4200399.5345391,"timestamp":1764685799018},"postHourTrading":{"tag":"盘后","latestPrice":3.34,"preClose":3.41,"latestTime":"17:42 EST","volume":37634,"amount":125988.056846,"timestamp":1764715346572},"volumeRatio":0.190775,"impliedVol":0.4864,"impliedVolPercentile":0.5568},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QTTB\",,,,,undefined,":{"symbol":"QTTB","floatShares":4728923,"roa":"-33.50%","roe":"-491.67%","lyrEps":-5.12108,"volumeRatio":0.190775,"shares":12197615,"dividePrice":0,"high":3.93,"amplitude":0.183246,"preClose":3.82,"low":3.23,"week52Low":1.345,"pbRate":"-2.25","psRate":"-2.84","week52High":28.06,"institutionHeld":0,"latestPrice":3.41,"committee":-0.981308,"eps":-6.578484,"divideRate":0,"volume":6420280,"delay":0,"ttmEps":-6.578484,"open":3.8,"prevYearClose":3.44,"prevWeekClose":2.19,"prevMonthClose":2.19,"prevQuarterClose":1.98,"fiveDayClose":2.04,"twentyDayClose":2.57,"sixtyDayClose":1.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/QTTB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"QTTB","fiscalQuarterEnding":"2025/09","expectedEps":-1.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2025-08-06","symbol":"QTTB","fiscalQuarterEnding":"2025/06","expectedEps":-1.14,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"pre","actualEps":-0.78},{"market":"US","date":"2025-03-11","symbol":"QTTB","fiscalQuarterEnding":"2024/12","expectedEps":-1.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2024-05-09","symbol":"QTTB","fiscalQuarterEnding":"2024/03","expectedEps":-1.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-13.15},{"market":"US","date":"2024-03-26","symbol":"QTTB","defaultRemindTime":1711459800000,"type":"split","dateTimestamp":1711425600000,"forFactor":18,"toFactor":1,"ratio":18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"QTTB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"QTTB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":4,"updateTime":1739332800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/QTTB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"QTTB","date":"2025-12-01","current":-0.580681,"percent":0.518703,"low":-10.694771,"twenty":-6.809794,"median":-0.654062,"eighty":-0.422683,"high":-0.277436,"avg":-3.205511,"sd":3.565119,"marketCap":26946530},"quantilePoints":[{"date":"2024-04-05","current":-4.597074,"twenty":-4.75645,"median":-4.597074,"eighty":-3.952906,"marketCap":247060524},{"date":"2024-04-12","current":-5.285192,"twenty":-4.79019,"median":-4.726928,"eighty":-4.38975,"marketCap":284042061},{"date":"2024-04-19","current":-5.411717,"twenty":-5.438798,"median":-4.767993,"eighty":-4.57532,"marketCap":290841892},{"date":"2024-04-26","current":-6.268535,"twenty":-5.702502,"median":-5.138689,"eighty":-4.700069,"marketCap":336889870},{"date":"2024-05-03","current":-5.72026,"twenty":-5.938238,"median":-5.411717,"eighty":-4.727594,"marketCap":307423936},{"date":"2024-05-10","current":-5.948893,"twenty":-5.966207,"median":-5.603724,"eighty":-4.749348,"marketCap":319711350},{"date":"2024-05-17","current":-6.881182,"twenty":-6.171755,"median":-5.72026,"eighty":-4.765329,"marketCap":369815368},{"date":"2024-05-24","current":-6.526024,"twenty":-6.419477,"median":-5.852334,"eighty":-4.856783,"marketCap":350728123},{"date":"2024-05-31","current":-7.119566,"twenty":-6.557988,"median":-5.896729,"eighty":-4.946904,"marketCap":326617228},{"date":"2024-06-07","current":-5.417118,"twenty":-6.655355,"median":-5.948893,"eighty":-5.16799,"marketCap":248515704},{"date":"2024-06-14","current":-5.122964,"twenty":-6.625166,"median":-5.89118,"eighty":-5.079231,"marketCap":235021098},{"date":"2024-06-21","current":-4.172821,"twenty":-6.589953,"median":-5.833467,"eighty":-4.901621,"marketCap":191432327},{"date":"2024-06-28","current":-3.969777,"twenty":-6.557988,"median":-5.738018,"eighty":-4.86516,"marketCap":182117467},{"date":"2024-07-05","current":-4.511228,"twenty":-6.526024,"median":-5.680305,"eighty":-4.760002,"marketCap":206957095},{"date":"2024-07-12","current":-5.841429,"twenty":-6.49406,"median":-5.603724,"eighty":-4.798567,"marketCap":267981374},{"date":"2024-07-15","current":-6.825412,"twenty":-6.526024,"median":-5.660327,"eighty":-4.813855,"marketCap":313122622},{"date":"2024-08-02","current":-9.884093,"twenty":-6.542006,"median":-5.670316,"eighty":-4.829142,"marketCap":453442638},{"date":"2024-08-09","current":-7.500596,"twenty":-6.710706,"median":-5.738018,"eighty":-4.87207,"marketCap":427886482},{"date":"2024-08-16","current":-7.75207,"twenty":-6.825412,"median":-5.856316,"eighty":-4.928392,"marketCap":442232352},{"date":"2024-08-23","current":-8.155846,"twenty":-7.24299,"median":-5.902278,"eighty":-4.94491,"marketCap":465266543},{"date":"2024-08-30","current":-8.295371,"twenty":-7.548702,"median":-6.028804,"eighty":-4.98294,"marketCap":473226002},{"date":"2024-09-06","current":-9.684274,"twenty":-7.772364,"median":-6.120922,"eighty":-4.998807,"marketCap":552458796},{"date":"2024-09-13","current":-9.610284,"twenty":-8.191784,"median":-6.244914,"eighty":-5.018839,"marketCap":548237871},{"date":"2024-09-20","current":-9.971779,"twenty":-8.294103,"median":-6.360654,"eighty":-5.041746,"marketCap":568860105},{"date":"2024-09-27","current":-9.599714,"twenty":-8.935493,"median":-6.526024,"eighty":-5.050076,"marketCap":547634882},{"date":"2024-10-04","current":-9.037388,"twenty":-9.107996,"median":-6.621961,"eighty":-5.093809,"marketCap":515555851},{"date":"2024-10-11","current":-9.978122,"twenty":-9.382394,"median":-6.703603,"eighty":-5.220301,"marketCap":569221899},{"date":"2024-10-18","current":-10.49394,"twenty":-9.484712,"median":-6.794175,"eighty":-5.315929,"marketCap":598647777},{"date":"2024-10-25","current":-10.06691,"twenty":-9.672968,"median":-6.825412,"eighty":-5.346971,"marketCap":574287009},{"date":"2024-10-31","current":-9.792089,"twenty":-9.748541,"median":-7.119566,"eighty":-5.360507,"marketCap":558609287},{"date":"2024-11-08","current":-9.443128,"twenty":-9.802236,"median":-7.283651,"eighty":-5.372344,"marketCap":572357443},{"date":"2024-11-15","current":-7.16039,"twenty":-9.789552,"median":-7.500596,"eighty":-5.379633,"marketCap":433998376},{"date":"2024-11-22","current":-5.434099,"twenty":-9.773909,"median":-7.256318,"eighty":-5.396215,"marketCap":329366155},{"date":"2024-11-29","current":-5.407973,"twenty":-9.752346,"median":-7.139978,"eighty":-5.371303,"marketCap":327782663},{"date":"2024-12-06","current":-4.760865,"twenty":-9.734588,"median":-6.825412,"eighty":-5.339276,"marketCap":288560806},{"date":"2024-12-13","current":-0.854102,"twenty":-9.716407,"median":-6.794175,"eighty":-5.114636,"marketCap":51767979},{"date":"2024-12-20","current":-0.671224,"twenty":-9.680505,"median":-6.703603,"eighty":-5.031844,"marketCap":40683541},{"date":"2024-12-27","current":-0.719455,"twenty":-9.66543,"median":-6.637987,"eighty":-4.975898,"marketCap":43606909},{"date":"2025-01-03","current":-0.69333,"twenty":-9.621313,"median":-6.605935,"eighty":-4.929676,"marketCap":42023418},{"date":"2025-01-10","current":-0.657156,"twenty":-9.603942,"median":-6.526024,"eighty":-4.86516,"marketCap":39830892},{"date":"2025-01-17","current":-0.631031,"twenty":-9.545173,"median":-6.362567,"eighty":-4.746844,"marketCap":38247401},{"date":"2025-01-24","current":-0.677253,"twenty":-9.492745,"median":-6.288512,"eighty":-4.6939,"marketCap":41048962},{"date":"2025-01-31","current":-0.655147,"twenty":-9.465263,"median":-6.219701,"eighty":-4.511228,"marketCap":39709085},{"date":"2025-02-07","current":-0.63505,"twenty":-9.453365,"median":-6.05877,"eighty":-3.980076,"marketCap":38491015},{"date":"2025-02-14","current":-0.538587,"twenty":-9.43896,"median":-5.948893,"eighty":-0.813105,"marketCap":32644278},{"date":"2025-02-21","current":-0.488345,"twenty":-9.423405,"median":-5.89118,"eighty":-0.724279,"marketCap":29599103},{"date":"2025-02-28","current":-0.450162,"twenty":-9.384931,"median":-5.843753,"eighty":-0.704182,"marketCap":27284770},{"date":"2025-03-07","current":-0.468249,"twenty":-9.351106,"median":-5.738018,"eighty":-0.689713,"marketCap":28381033},{"date":"2025-03-14","current":-0.470191,"twenty":-9.227225,"median":-5.670316,"eighty":-0.675243,"marketCap":22443611},{"date":"2025-03-21","current":-0.53152,"twenty":-9.18875,"median":-5.509385,"eighty":-0.665195,"marketCap":25371039},{"date":"2025-03-28","current":-0.482968,"twenty":-9.161872,"median":-5.425609,"eighty":-0.655147,"marketCap":23053492},{"date":"2025-04-04","current":-0.408861,"twenty":-9.091808,"median":-5.407973,"eighty":-0.643893,"marketCap":19516184},{"date":"2025-04-11","current":-0.429305,"twenty":-9.050837,"median":-5.380674,"eighty":-0.631433,"marketCap":20491993},{"date":"2025-04-17","current":-0.472746,"twenty":-9.045443,"median":-5.362133,"eighty":-0.622992,"marketCap":22565587},{"date":"2025-04-25","current":-0.472746,"twenty":-9.037388,"median":-5.336421,"eighty":-0.57878,"marketCap":22565587},{"date":"2025-05-02","current":-0.39864,"twenty":-8.919003,"median":-5.165991,"eighty":-0.546852,"marketCap":19028279},{"date":"2025-05-09","current":-0.314156,"twenty":-8.857697,"median":-5.050076,"eighty":-0.534567,"marketCap":18784327},{"date":"2025-05-16","current":-0.354955,"twenty":-8.778159,"median":-5.035734,"eighty":-0.528965,"marketCap":21223850},{"date":"2025-05-23","current":-0.336596,"twenty":-8.694918,"median":-4.992187,"eighty":-0.51491,"marketCap":20126064},{"date":"2025-05-30","current":-0.385555,"twenty":-8.584144,"median":-4.945951,"eighty":-0.506094,"marketCap":23053492},{"date":"2025-06-06","current":-0.375355,"twenty":-8.389867,"median":-4.923647,"eighty":-0.48773,"marketCap":22443611},{"date":"2025-06-13","current":-0.346796,"twenty":-8.305941,"median":-4.87898,"eighty":-0.485012,"marketCap":20735945},{"date":"2025-06-20","current":-0.325376,"twenty":-8.294103,"median":-4.767993,"eighty":-0.472746,"marketCap":19455195},{"date":"2025-06-27","current":-0.316196,"twenty":-8.276767,"median":-4.744886,"eighty":-0.463426,"marketCap":18906303},{"date":"2025-07-03","current":-0.293756,"twenty":-8.257318,"median":-4.726928,"eighty":-0.447751,"marketCap":17564565},{"date":"2025-07-11","current":-0.677271,"twenty":-8.238715,"median":-4.597074,"eighty":-0.434085,"marketCap":40496081},{"date":"2025-07-18","current":-0.473274,"twenty":-8.204468,"median":-4.511228,"eighty":-0.43275,"marketCap":28298466},{"date":"2025-07-25","current":-0.471234,"twenty":-8.162188,"median":-4.172821,"eighty":-0.434085,"marketCap":28176490},{"date":"2025-08-01","current":-0.452874,"twenty":-8.09158,"median":-3.876104,"eighty":-0.433118,"marketCap":27078705},{"date":"2025-08-08","current":-0.417439,"twenty":-7.990847,"median":-0.854102,"eighty":-0.431093,"marketCap":21833730},{"date":"2025-08-15","current":-0.438428,"twenty":-7.911731,"median":-0.739552,"eighty":-0.423091,"marketCap":22931516},{"date":"2025-08-22","current":-0.437262,"twenty":-7.782512,"median":-0.719455,"eighty":-0.423091,"marketCap":22870528},{"date":"2025-08-29","current":-0.412775,"twenty":-7.72332,"median":-0.705388,"eighty":-0.422172,"marketCap":21589778},{"date":"2025-09-05","current":-0.387122,"twenty":-7.662014,"median":-0.692325,"eighty":-0.419594,"marketCap":20248040},{"date":"2025-09-12","current":-0.438428,"twenty":-7.579145,"median":-0.689311,"eighty":-0.417439,"marketCap":22931516},{"date":"2025-09-19","current":-0.405779,"twenty":-7.530963,"median":-0.677262,"eighty":-0.417439,"marketCap":21223850},{"date":"2025-09-26","current":-0.438428,"twenty":-7.458231,"median":-0.675243,"eighty":-0.417439,"marketCap":22931516},{"date":"2025-10-03","current":-0.482737,"twenty":-7.286722,"median":-0.66821,"eighty":-0.417768,"marketCap":25249063},{"date":"2025-10-10","current":-0.755588,"twenty":-7.269646,"median":-0.665195,"eighty":-0.419083,"marketCap":39520272},{"date":"2025-10-17","current":-0.839542,"twenty":-7.219361,"median":-0.673234,"eighty":-0.419594,"marketCap":43911414},{"date":"2025-10-24","current":-0.652977,"twenty":-7.152225,"median":-0.675243,"eighty":-0.421731,"marketCap":34153322},{"date":"2025-10-31","current":-0.643649,"twenty":-7.071889,"median":-0.671224,"eighty":-0.422103,"marketCap":33665417},{"date":"2025-11-07","current":-0.541038,"twenty":-6.870028,"median":-0.665195,"eighty":-0.422103,"marketCap":28298466},{"date":"2025-11-14","current":-0.515386,"twenty":-6.825412,"median":-0.656232,"eighty":-0.422103,"marketCap":26956729},{"date":"2025-11-21","current":-0.564098,"twenty":-6.824371,"median":-0.655309,"eighty":-0.422137,"marketCap":23747399},{"date":"2025-11-28","current":-0.640091,"twenty":-6.820206,"median":-0.655147,"eighty":-0.422275,"marketCap":26946530},{"date":"2025-12-01","current":-0.640091,"twenty":-6.809794,"median":-0.654062,"eighty":-0.422683,"marketCap":26946530}],"updateTime":1764682079821},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"QTTB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588377769","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588377769","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588377769?lang=en_us&edition=fundamental","pubTime":"2025-12-02 02:32","pubTimestamp":1764613968,"startTime":"0","endTime":"0","summary":"Q32 Bio's  shares doubled amid heavy trading after the company said Monday it sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics .More than 157.3 million shares of Q32 Bio traded intraday compared with a daily average of about 223,000.Kala Bio  said Monday it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the company's non-voting convertible preferred stock.Effective immediately, Lazar has been appointed Kala's chief executive officer and chairman. Former CEO Todd Bazemore continues to serve on the board.Shares surged 58% as intraday trading volume catapulted to over 147.5 million from a daily average of about 1.7 million.Belite Bio  said Monday its phase 3 trial of Tinlarebant to treat Stargardt disease type 1 met its primary efficacy endpoint.Shares advanced 8.4% as intraday trading volume climbed to more than 611,000 from a daily average of about 90,000.Price: 4.40, Change: +2.21, Percent Change: +","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","KALA","QTTB","BK4007","AKBA","BLTE"],"gpt_icon":0},{"id":"2588774604","title":"BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2588774604","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588774604?lang=en_us&edition=fundamental","pubTime":"2025-12-02 00:53","pubTimestamp":1764607982,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa ResourcesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nL6N3X70KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INR","LUV","IDA","KGS","NVDY","FLYE","TRGP","QTTB","LEG","AAL","NVDS","AHMA","NVDU","USAC","FCEL","UAL","SNPS","FANG","CDE","NVAX","DARE","TSYW.SI","CPNG","HL","PAVS","BLTE","NVDD","ZS","OMC","MRNA","IDYA","ODFL","EXC","ACN","CLNE","ALT"],"gpt_icon":1},{"id":"2588577926","title":"Why Is Small-Cap Q32 Bio Stock Soaring On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588577926","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588577926?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:43","pubTimestamp":1764600180,"startTime":"0","endTime":"0","summary":"Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/01/Medical-Business-Handshake.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/01/Medical-Business-Handshake.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49136089/why-is-small-cap-q32-bio-stock-soaring-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49136089/why-is-small-cap-q32-bio-stock-soaring-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","QTTB","AKBA"],"gpt_icon":0},{"id":"2588778401","title":"Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778401","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778401?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:40","pubTimestamp":1764596454,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics (AKBA) said Monday that it has built a rare kidney disease pipeline around a complement inhibitor acquired from Q32 Bio (QTTB) and an existing drug now in a mid-stage study for foc","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AKBA","BK4139","QTTB"],"gpt_icon":0},{"id":"2588819778","title":"BRIEF-Akebia Announces Establishment Of Rare Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588819778","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588819778?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:21","pubTimestamp":1764595262,"startTime":"0","endTime":"0","summary":"BRIEF-Akebia Announces Establishment Of Rare Kidney Disease PipelineDec 1 (Reuters) - Akebia Therapeutics Inc AKBA.O:AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINEAKEBIA THERAPEUTICS: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","AKBA","BK4139"],"gpt_icon":0},{"id":"2588720304","title":"BRIEF-Q32 Bio Sells Complement Inhibitor Adx-097","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720304","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720304?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:03","pubTimestamp":1764594181,"startTime":"0","endTime":"0","summary":"BRIEF-Q32 Bio Sells Complement Inhibitor Adx-097Dec 1  - Q32 BIO SELLS COMPLEMENT INHIBITOR ADX-097Q32 BIO INC - $12 MILLION PAYMENTS EXPECTED TO EXTEND CASH RUNWAY INTO SECOND HALF OF 2027Q32 BIO INC - ELIGIBLE FOR UP TO $592 MILLION INCLUDING ROYALTIESSource text: ID:nPn4S4bM2a ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA5XFQDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB","AKBA"],"gpt_icon":0},{"id":"2588727118","title":"Q32 Bio Sells Lead Product Candidate to Akebia Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727118","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727118?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:46","pubTimestamp":1764593160,"startTime":"0","endTime":"0","summary":"Q32 Bio said it sold the lead product candidate from its tissue-targeted complement inhibitor platform to Akebia Therapeutics.The Waltham, Mass., biotech company said Monday it will receive $12 million in upfront payments and a near-term milestone. Q32 Bio said it will be eligible to receive a total of up to $592 million, pending the achievement of certain development, regulatory and commercial milestones, in addition to tiered royalties of up to a mid-teen percent of annual net sales.The transaction will strengthen the company's cash position, extending its runway into the second half of 2027, while also enabling it to focus on the advancement of bempikibart, its treatment for autoimmune and inflammatory diseases, Q32 Bio said.Shares of Q32 jumped 78% in premarket trading, to $3.90, while Akebia's stock was roughly flat.Akebia said the product candidate, AKB-097, is believed to have applicability across a wide range of complement-mediated rare kidney diseases.\"While our commercial and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QTTB","AKBA","BK4139"],"gpt_icon":0},{"id":"2588119727","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2588119727","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588119727?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:45","pubTimestamp":1764593159,"startTime":"0","endTime":"0","summary":"Q32 Bio  shares were 71% higher pre-bell Monday after the company said it has sold alopecia areata drug candidate ADX-097 to Akebia Therapeutics .Belite Bio  stock was up 17% after the company said that a late-stage trial of Tinlarebant to treat Stargardt eye disease met its primary efficacy endpoint.Canadian Solar  shares were 13% higher after the company said it will resume direct oversight of its US operations.INVO Fertility  stock was up 12% after the company said it plans to acquire fertility clinic Family Beginnings.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","IVF","BK4588","BLTE","BK4141","BK4585","BK4519","BK4007","AKBA","QTTB","BK4139","BK4526"],"gpt_icon":1},{"id":"2588082724","title":"Akebia Therapeutics Acquires Global Rights to AKB-097 from Q32 Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2588082724","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588082724?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590425,"startTime":"0","endTime":"0","summary":"Akebia Therapeutics Inc. announced the signing of an Asset Purchase Agreement with Q32 Bio, under which Akebia acquired global rights to Q32 Bio's ADX-097, now referred to as AKB-097. As part of the agreement, Akebia made an upfront payment of $7.0 million to Q32 Bio and will make an additional $3.0 million payment six months after the closing. The agreement also includes provisions for potential additional development, regulatory, and commercial milestone payments, as well as tiered royalties on annual net sales of AKB-097.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the inf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL1kPh8k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","AKBA","LU2210149790.SGD","LU0314104364.USD","NDAQ","BK4139","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","QTTB","BK4585","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2588787724","title":"Akebia Announces Establishment of Rare Kidney Disease Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2588787724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588787724?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AKBA","QTTB","BK4139"],"gpt_icon":0},{"id":"2588724049","title":"Akebia Therapeutics: Phase 2 Basket Trial Planned to Evaluate Complement Inhibitor in Multiple Rare Kidney Disease Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724049?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139","AKBA"],"gpt_icon":0},{"id":"2588724046","title":"Akebia Therapeutics Inc: Both Trials Planned to Start Treating Subjects in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724046?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139","AKBA"],"gpt_icon":0},{"id":"2588247797","title":"Akebia Therapeutics: Acquires Next Generation Tissue-Targeted C3d-Factor H Fusion Protein Complement Inhibitor From Q32 Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2588247797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588247797?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139","AKBA"],"gpt_icon":0},{"id":"2588240297","title":"Akebia Therapeutics Inc: Phase 2 Trial of Praliciguat Initiated in Focal Segmental Glomerulosclerosis (Fsgs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588240297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588240297?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2STW5D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QTTB","AKBA"],"gpt_icon":0},{"id":"2588772472","title":"Q32 Bio Inc - Eligible for up to $592 Mln Including Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2588772472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588772472?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA5XFQDT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AKBA","QTTB","BK4139"],"gpt_icon":0},{"id":"2588724776","title":"Q32 Bio Inc - $12 Mln Payments Expected to Extend Cash Runway Into Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724776","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724776?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA5XFQDT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QTTB","BK4139","AKBA"],"gpt_icon":0},{"id":"2588724011","title":"Press Release: Q32 Bio Sells Complement Inhibitor ADX-097","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724011","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724011?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata --. -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 --. -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these programs --. Q32 Bio's tissue-targeted complement platform is designed to inhibit complement activation in the tissue while minimizing systemic complement blockade, a key differentiator versus current complement therapeutics.  The platform is proprietary to Q32 Bio and developed with foundational science from the University of Colorado Anschutz Medical Campus. Beyond ADX-097, discovery and earlier development efforts include ADX-096, a C3d mAb -- CR1 fusion protein with preclinical data supportive of its use in ophthalmologic indications as well as potential utility ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADX","AA","BK4588","BK4585","QTTB","AKBA","BK4153","BK4139"],"gpt_icon":0},{"id":"2584291776","title":"Q32 Bio (QTTB) Receives a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584291776","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584291776?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:55","pubTimestamp":1763387734,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jay Olson maintained a Buy rating on Q32 Bio on November 14 and set a price target of $20.00. The company’s shares closed last ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/q32-bio-qttb-receives-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/q32-bio-qttb-receives-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","BK4139","BK4127","QTTB"],"gpt_icon":0},{"id":"2584819643","title":"Wells Fargo Remains a Hold on Q32 Bio (QTTB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584819643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584819643?lang=en_us&edition=fundamental","pubTime":"2025-11-17 16:25","pubTimestamp":1763367937,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Derek Archila maintained a Hold rating on Q32 Bio on November 14 and set a price target of $10.00. The company’s shares closed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-remains-a-hold-on-q32-bio-qttb-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-remains-a-hold-on-q32-bio-qttb-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0256863811.USD","LU0310799852.SGD","LU1069347547.HKD","BK4559","BK4585","LU0477156953.USD","LU1668664300.SGD","LU1280957306.USD","LU0029864427.USD","LU0251142724.SGD","BK4501","LU0106831901.USD","LU0314106906.USD","LU1267930490.SGD","LU1035773651.USD","LU1791807156.HKD","LU0267386448.USD","BK4139","LU0128525929.USD","LU0048573561.USD","LU0708994859.HKD","LU0787776722.HKD","LU1814569148.SGD","LU1267930573.SGD","IE0002270589.USD","IE00B19Z3581.USD","LU0130517989.USD","LU0417517546.SGD","LU0208291251.USD","LU0742534661.SGD","LU1267930227.SGD","LU0052756011.USD","LU2461242641.AUD","IE000M9KFDE8.USD","LU0648001328.SGD","LU0175139822.USD","LU0251131958.USD","LU0868494708.USD","LU0980610538.SGD","QTTB","LU0149725797.USD","LU0640476718.USD","LU0310800379.SGD","LU0971096721.USD","LU1074936037.SGD","LU0320765489.SGD","LU1506573853.SGD","LU0683600562.USD","LU0942090050.USD","LU0868494617.USD"],"gpt_icon":0},{"id":"2583562399","title":"Q32 Bio Inc. reports Q3 net loss of $7.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562399","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583562399?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:59","pubTimestamp":1763035163,"startTime":"0","endTime":"0","summary":"Q32 Bio Inc. reported a net loss of $7.4 million, or $0.60 per share, for the third quarter of 2025, compared to a net loss of $17.6 million, or $1.46 per share, for the same period in 2024. Research and development expenses decreased to $3.6 million from $14.3 million, primarily due to lower development costs for bempikibart, reduced expenses from the discontinued ADX-097 program, and lower personnel-related costs. General and administrative expenses were $4.0 million, down from $4.5 million, mainly due to decreased personnel and professional service costs. As of September 30, 2025, cash and cash equivalents totaled $49.0 million, expected to fund operations into 2027. The company completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial, with a topline data readout expected in mid-2026, and continues dosing in the Part A open-label extension.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLjjQVG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}